PT - JOURNAL ARTICLE AU - Anna Jamnitski AU - Johannes H. Levels AU - Inge A. van den Oever AU - Michael T. Nurmohamed TI - High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study AID - 10.3899/jrheum.121358 DP - 2013 Jun 01 TA - The Journal of Rheumatology PG - 825--830 VI - 40 IP - 6 4099 - http://www.jrheum.org/content/40/6/825.short 4100 - http://www.jrheum.org/content/40/6/825.full SO - J Rheumatol2013 Jun 01; 40 AB - Objective. We investigated changes in high-density lipoprotein (HDL) profiling in patients with rheumatoid arthritis who started treatment by taking tumor necrosis factor (TNF) inhibitors. The patients were stratified for European League Against Rheumatism (EULAR) response. Methods. A group of 100 patients naive for TNF inhibitors at baseline were randomly selected from 204 adalimumab-treated and 203 etanercept-treated patients on the basis of their EULAR response. HDL profiling was measured using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Results. In EULAR good responders, mass charged markers representing serum amyloid A (SAA-1 and -2) decreased significantly after 4 months’ therapy. There were no significant differences in HDL profiling in EULAR nonresponders. Conclusion. Effective suppression of inflammation with TNF inhibitors results in favorable changes in HDL composition.